Ladenburg analyst Aydin Huseynov downgraded Bellicum Pharmaceuticals to Neutral from Buy after the company announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BLCM:
- BLCM Plummets on Stopping Trials of BPX-601 and BPX-603
- Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives
- Bellicum Pharmaceuticals to discontinue GoCAR-T trials, evaluate alternatives
- Bellicum Pharmaceuticals presents early Phase 1 results for BPX-601
- CORRECTION — Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)